Proteomics in clinical practice

Proteomics involves the comprehensive evaluation of protein structure and function to understand biological systems.
Utilizes mass spectrometry (MS) for protein profiling.
Major challenge remains biomarker discovery due to complexities and protein dynamics.
Combining proteomics with genomics and bioinformatics enhances understanding of biological systems and disease mechanisms.

Proteome: The entire set of proteins expressed by a genome, cell, tissue, or organism.
Proteomics studies interactions, functions, composition, and structures of proteins.
Provides deeper insights than genomics due to temporal and environmental variations in protein expression.

Mass Spectrometry (MS): Essential tool for profiling proteins.
Electrophoresis Techniques:
- 1D Gel Electrophoresis (1-DE): Used for protein separation based on molecular weight.
- 2D Gel Electrophoresis (2-DE): Separates proteins in two dimensions—by their isoelectric point and molecular weight allowing deeper analysis of protein forms and modifications.
Gel-Free Technologies: High-throughput methods for protein identification such as shotgun proteomics and microarrays.

Expression Proteomics: Focuses on qualitative and quantitative analysis of protein expression levels across different conditions.
Structural Proteomics: Utilizes techniques like NMR and X-ray crystallography to unveil 3D structures of proteins and their interactions.
Functional Proteomics: Investigates protein functions and interactions, revealing biological roles and signaling pathways.

Sample Preparation
- Critical for the success of proteomics.
- Involves protein extraction, solubilization, and denaturation.
Protein Separation
- Techniques include PAGE, chromatography, and various forms of affinity chromatography.
Protein Identification & Quantification
- Post-separation, proteins are identified using MS, Edman sequencing, or microarrays.

Biomarker: A biological indicator of a disease or health status.
Biomarkers can be found in body fluids like urine, serum, and exhaled breath.
Categories of cancer biomarkers:
- Predictive: Indicate likely response to treatment (e.g., HER2 in breast cancer).
- Prognostic: Provide information about disease outcomes (e.g., 21-gene recurrence score).
- Diagnostic: Confirm presence of disease (e.g., stool DNA tests for colorectal cancer).

Proteomics aids in understanding protein interactions that influence disease pathways for drug development.
New methods evolve to address limitations in detecting low-abundance proteins crucial for therapies.
Technologies such as MS and protein chips are prevalent in this endeavor.

Oncoproteomics: Specific to cancer biomarkers and drug development.
Utilizes techniques like microarrays and mass spectrometry imaging (MSI) to characterize tumors and refine therapies.
Studies on acute myeloid leukemia (AML) identify specific proteins associated with disease progression, aiding personalized treatments.

Variable protein expression affected by environmental factors and cell types complicate analyses.
Lack of standardized methods compared to genomics.
Sample preparation significantly influences results; varying techniques can lead to discrepancies in MS data.

Proteomics stands as a pivotal anti-disease strategy by identifying novel biomarkers and contributing to drug discovery.
Comprehensive understanding through proteomics catalyzes breakthroughs in therapeutic design and precision medicine.